Nov 16, 2020 5:15pm EST Medexus Pharmaceuticals Reports Operating and Financial Results for the Three- and Six-Month Periods Ending September 30, 2020
Nov 16, 2020 8:00am EST Medexus Reaches 50% Enrollment in IXINITY® Phase 4 Clinical Trial Targeting Label Expansion for Pediatric Hemophilia B Patients
Oct 30, 2020 12:30pm EDT Medexus Announces Engagement of Westmount Capital and Equity Incentive Grants to Insiders
Sep 25, 2020 8:30am EDT Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy
Sep 18, 2020 10:38am EDT Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results
Sep 10, 2020 9:20am EDT Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas
Aug 24, 2020 7:57pm EDT Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants
